Skip to content

SVRA: Held by 5 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Free TrialStart 14-Day Free Trial

Home›Companies›Savara Inc. (SVRA)

Savara Inc.

SVRA

Held by 5 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

5 funds opened new positions. Next phase3 readout (Molgramostim): Nov 2023. Short interest: 24.8% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Matthew PaulsIPO: 2017Website ↗

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.5/10

5 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jun 2027●●

Held by 5 specialist funds●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

5 specialist funds hold SVRA with a Phase 3 in 259 days for Molgramostim (Autoimmune Pulmonary Alveolar Proteinosis)

RTW Investments OrbiMed Advisors Driehaus Capital Perceptive Advisors Deerfield Management

Fund Holdings

5 fund convergence

RTW InvestmentsHeld 3Q

OrbiMed AdvisorsHeld 2Q ↑

Driehaus Capital

Perceptive Advisors

Deerfield ManagementHeld 7Q ↑

Position history (shares)

RTW Investments

3Q OrbiMed Advisors

2Q Deerfield Management

AI Signal

SVRA Signal Note

OrbiMed increased its stake in Savara by 3.3M shares (+84% position growth), now representing $24.4M across five specialist healthcare funds—notable convergence around a rare disease play. The thesis hinges on molgramostim's phase 3 readout in autoimmune pulmonary alveolar proteinosis, though catalyst timing appears inconsistent in disclosed dates (both 2023-11 and 2027-06 listed); clarification needed on which is primary.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Feb 17, 2026

$132.2M

3 funds

May 15, 2026

$110.1M

3 funds

May 29, 2026

$0

0 funds

Aug 14, 2026

$144.6M

3 funds

+428% total institutional value over 9 quarters

Short Interest

Float data divergenceHigh short interestSI rising 7 periods (+94.4%)

Short Shares

43.56M

Change

+5.2%

Days to Cover

22.8

% of Float

24.8%

Settlement

Sep 30, 2026

Short interest over 10 periods

Catalysts

Phase 2Q4 2014Vancomycin hydrochloride inhalation powderCystic FibrosisNCT01746095

Primary: Change From Baseline in MRSA Sputum Density. (Day 29 of treatment period)Enrollment:87/87Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2019MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT02702180

Primary: Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment (From baseline to 24 weeks)Enrollment:139/139Sites: 30RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2019Inhaled molgramostimMycobacterium Infections, NontuberculousNCT03421743

Primary: Number of Participants With Sputum Culture Conversion to Negative (48 weeks)Enrollment:32/32Sites: 5NON_RANDOMIZED, TREATMENT

Phase 3Q3 2020Vancomycin inhalation powderMRSA, Cystic FibrosisNCT03181932

Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted (Baseline and Week 4, 12 and 20)Enrollment:188/188Sites: 71RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ4 2020Molgramostim nebulizer solutionMycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)NCT03597347

Primary: Number of Participants With Sputum NTM Culture Conversion to Negative (48 weeks)Enrollment:14/14Sites: 5NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2021MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT03482752

Primary: Number of Treatment-emergent Adverse Events (TEAEs) (139 weeks)Enrollment:60/60Sites: 13NA, TREATMENT

Phase 3Q4 2023MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT04544293

Primary: Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24 (From Baseline to Week 24)Enrollment:164/164Sites: 54RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027MolgramostimAutoimmune Pulmonary Alveolar ProteinosisNCT06431776

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/AEcoR1 Capital5.3%Feb 14, 2022

SC 13G/AEcoR1 Capital5.3%Feb 16, 2021

SC 13G/AEcoR1 Capital5.3%Feb 12, 2021

SC 13GEcoR1 Capital8.3%Jan 6, 2020

Recent News & Research

PubMed

Molgramostim improves exercise distance and duration in autoimmune pulmonary alveolar proteinosis: exploratory IMPALA-2 trial data.

# Savara Investment Summary **Clinical Finding:** Molgramostim demonstrated statistically significant improvements in exercise capacity (distance and duration) in autoimmune pulmonary alveolar proteinosis (aPAP) patients in the IMPALA-2 trial, addressing a key functional limitation in this rare lung disease. **Investment Implication:** This data supports molgramostim's potential to address unmet needs in aPAP beyond symptom management, which could strengthen Savara's regulatory positioning and commercial viability in a small but underserved patient population where functional improvements directly correlate with quality of life and treatment adoption. --- *Note: Exercise capacity metrics are clinically meaningful endpoints in pulmonary diseases and may support regulatory pathways (particularly if correlated with longer-term clinical outcomes), though the exploratory nature of this data warrants review of primary endpoint results and trial design details.*

Sep 22, 2026

Position Details

RTW InvestmentsHELDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

20 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

CMPS1 fund BSX1 fund STTK1 fund SPRY1 fund AORT1 fund DRUG1 fund CAI1 fund ELVN1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: